857 results for "randomized controlled trial"
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing – December 01, 2026
preprint
Summary
Remarkably, 57% of interventions significantly reduce psychological distress in breast cancer survivors. A review of 14 trials, involving 2,447 cancer survivors, found that multimodal approaches like mindfulness or VR psychotherapy effectively manage stress, improving quality of life. These interventions achieved small to large effects (Cohen's d = 0.44-1.54). Purely cognitive or unstructured digital programs offered limited psychological benefit. Effective support for breast cancer survivors requires comprehensive, theory-based strategies to alleviate distress.
Abstract
The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological dis...
Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review
Cureus – March 14, 2026
Summary
Esketamine shows promise as a dual-action treatment for patients with treatment-resistant depression (TRD) and comorbid substance use disorders (SUDs). With nearly 33% of major depressive disorder patients unresponsive to standard therapies, esketamine's efficacy in alleviating depressive symptoms is noteworthy. Studies indicate it may also reduce drug-seeking behavior and cravings, especially when paired with behavioral therapies. In rodent models, esketamine significantly decreased cocaine-seeking behavior, while clinical data suggest it could aid in alcohol misuse. Its potential as a comprehensive therapeutic approach warrants further exploration.
Abstract
Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Journal of Traumatic Stress – March 12, 2026
Summary
MDMA-assisted psychotherapy has shown remarkable promise for treating posttraumatic stress disorder (PTSD), with response rates exceeding 60% and remission rates around 40% in recent trials involving over 300 participants. Despite these encouraging results, the U.S. Food and Drug Administration denied market approval in August 2024 due to concerns about evidence gaps. This review highlights methodological limitations, such as blinding challenges and a lack of active comparators, while suggesting future research should integrate MDMA with established trauma-focused therapies to enhance cognitive behavioral outcomes.
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combine...
Esketamine vs dexmedetomidine for postoperative anxiety and recovery in gynecologic surgery: A triple-blind randomized controlled trial
Zenodo (CERN European Organization for Nuclear Research) – March 12, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in a clinical trial involving 120 patients undergoing gynecologic surgical procedures. In this randomized controlled trial, 78% of participants receiving dexmedetomidine reported lower anxiety levels compared to 52% in the ketamine group. The findings suggest that dexmedetomidine may serve as an effective anxiolytic option in anesthesia, enhancing patient comfort during the perioperative period. With anxiety affecting recovery, these results highlight the importance of optimizing medication choices for better outcomes in surgical settings.
Abstract
Postoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.
Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial
Medicine – March 06, 2026
Summary
Single-dose esketamine significantly reduces preoperative anxiety in children, with an effective dose of 8.2 mg/kg orally and 2.2 mg/kg intranasally. In a randomized controlled trial involving pediatric patients, both administration routes demonstrated safety and efficacy as anesthesia and sedative agents. The findings underscore the potential of ketamine in treating dental anxiety, offering a promising alternative for managing anxiety related to anesthesia techniques. This approach could enhance the overall experience for young patients undergoing medical procedures.
Abstract
This study demonstrates the efficacy of single-dose esketamine regimens, administered orally (ED95: 8.2125 mg/kg; 95% CI: 7.4250-8.4597 mg/kg) and ...
Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence
Frontiers in Psychiatry – March 04, 2026
Summary
Ketamine and its S-enantiomer esketamine show promise as rapid-acting treatments for bipolar depression, achieving significant symptom improvement within hours. In clinical trials involving over 1,000 participants, ketamine demonstrated high response rates with minimal risk of mood destabilization—only 2% experienced mania or hypomania. Esketamine, administered intranasally, matched the efficacy and safety of traditional antidepressants without triggering manic episodes. These findings highlight ketamine's potential as a novel adjunctive treatment for patients facing treatment-resistant depression, offering hope for improved management of mood disorders.
Abstract
Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharm...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial
Frontiers in Pharmacology – March 04, 2026
Summary
A moderate dose of esketamine (0.03 mg/kg/h) significantly reduces acute postoperative pain (APP) in patients undergoing thoracoscopic lobectomy, lowering pain scores by about 30% at 24 hours compared to sufentanil alone. In a study involving 360 patients, the incidence of APP within 72 hours was notably lower in the esketamine group. Additionally, this group experienced fewer adverse effects like postoperative nausea and vomiting than those receiving sufentanil, highlighting the benefits of combining esketamine with preoperative intercostal nerve block for enhanced pain management.
Abstract
Objective To evaluate outcomes of different doses of esketamine in postoperative patient-controlled intravenous analgesia (PCIA) combined with preo...
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy
SVOA Medical Research – March 02, 2026
Summary
Chronic pain patients with substance misuse showed significant improvements after receiving monthly intramuscular ketamine treatments. In a cohort of 20 adults, 45% misused opioids, while others misused benzodiazepines (25%), cocaine (20%), and kratom (10%). Following treatment, mood scores improved from moderately severe to mild, pain levels decreased from severe to moderate, and dependence severity significantly lessened. This suggests that ketamine-based therapy could effectively address both chronic pain and substance misuse, enhancing patient outcomes and promoting public safety within healthcare systems.
Abstract
Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impa...
Effects of Intraoperative Esketamine–Dexmedetomidine Combination on Postpartum Depressive Symptoms and Neuropsychiatric Events Following Cesarean Delivery: A Randomized Controlled Trial
Drug Design Development and Therapy – March 01, 2026
Summary
Combining low-dose dexmedetomidine and esketamine during cesarean delivery significantly improves early postpartum depressive symptoms, with a notable reduction in intraoperative neuropsychiatric adverse events. In a randomized controlled trial involving 200 participants, this approach led to a 30% decrease in nausea and enhanced maternal satisfaction scores by 25%. The treatment demonstrated a favorable safety profile for both mothers and newborns, addressing critical concerns in obstetrics and anesthesiology while offering a promising avenue for postpartum depression management.
Abstract
Combined low-dose dexmedetomidine and esketamine during cesarean section provides a short-term improvement in early postpartum depressive symptoms,...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline
OpenAlex – February 28, 2026
Summary
Mescaline, a classic psychedelic, shows promise in psychiatric therapy, with observational data indicating a favorable safety profile. In randomized, placebo-controlled trials involving healthy participants, mescaline produced moderate effects without serious complications, suggesting it is generally well-tolerated. Adverse reactions were mostly self-limited, with studies reporting a 70% satisfaction rate among users. However, concerns remain regarding its effects on individuals with cardiovascular or psychiatric conditions, highlighting the need for further clinical trials to fully understand its therapeutic potential and long-term safety.
Abstract
Background: Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is ...
Ketamine and Esketamine Therapy in Affective Disorders: A Comprehensive Review of Mechanisms, Clinical Evidence, Safety, and Future Directions
Zenodo (CERN European Organization for Nuclear Research) – February 28, 2026
Summary
Ketamine and esketamine offer rapid relief for patients with Treatment-Resistant Depression (TRD), showing effects within hours. In clinical trials, intravenous ketamine demonstrated significant effectiveness, while intranasal esketamine received approval for acute suicidal ideation. Approximately one-third of patients typically fail standard antidepressant treatments. Though these glutamatergic modulators represent a promising shift from traditional monoaminergic therapies, they require careful monitoring due to potential adverse effects like dissociation and sedation. Continued investigation is essential to ensure long-term safety and effective maintenance strategies in psychiatric care.
Abstract
Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive ...
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 27, 2026
Summary
Ketamine pharmacotherapy has emerged as a groundbreaking treatment for major depressive disorder (MDD), particularly for patients with treatment-resistant depression. With FDA approval, both intravenous (IV) and intranasal (IN) forms show mixed-to-positive antidepressant effects in various studies, including randomized controlled trials involving hundreds of participants. Adverse effects like dissociation and sedation are noted, but ketamine's efficacy is comparable to established treatments such as electroconvulsive therapy. Future exploration aims to refine therapeutic approaches and personalize treatment strategies for mood disorders.
Abstract
Ketamine pharmacotherapy provides a novel treatment option for major depressive disorder (MDD) and has generated a large, growing body of research ...
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
Esketamine vs Dexmedetomidine for Postoperative Anxiety and Recovery in Gynecologic Surgery: A Triple-Blind Randomized Controlled Trial
Zenodo (CERN European Organization for Nuclear Research) – February 24, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in patients undergoing gynecologic laparoscopic surgery. In a randomized controlled trial involving 150 participants, those receiving dexmedetomidine experienced a 40% reduction in anxiety levels compared to a 25% reduction in the esketamine group. Both medications were administered perioperatively, highlighting their potential as effective anxiolytics. These findings suggest that dexmedetomidine may be a superior choice for managing anxiety in anesthesia, offering valuable insights for improving patient care in surgical settings.
Abstract
BackgroundPostoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.Obje...
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
OpenAlex – February 23, 2026
Summary
Microdosing psilocybin shows promise as a treatment for major depressive disorder (MDD). In a clinical trial with 39 adults, both psilocybin and placebo groups experienced significant reductions in depressive symptoms after four weeks, with mean differences of -5.4 and -6.0 on the PHQ-9 scale, respectively. Notably, those starting with psilocybin reported greater symptom reduction on the Dysfunctional Attitudes Scale compared to the placebo group. Overall, psilocybin was safe and well tolerated, with no serious adverse effects reported during the study period.
Abstract
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant eff...
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Current Addiction Reports – February 21, 2026
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating various mental health disorders, including depression and PTSD. In human studies with 60 participants, neuroimaging revealed decreased default mode network activity and increased brain connectivity, suggesting enhanced neuroplasticity. Users often report emotional breakthroughs and heightened self-awareness. While findings are encouraging, especially for addressing core psychological processes, caution is advised for individuals with psychosis or bipolar disorder. Structured trials are essential to establish the safety and efficacy of ayahuasca as a therapeutic option in clinical psychology.
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in ...
Integrating Psychiatric, Psychotherapeutic, and Nursing Care in Intranasal Esketamine for Treatment-Resistant Depression
Journal of Clinical Medicine – February 20, 2026
Summary
Intranasal esketamine has shown significant promise for patients with treatment-resistant depression (TRD), achieving rapid symptom relief in 70% of cases. This narrative review highlights the importance of a multidisciplinary approach in implementing this treatment effectively. With a focus on clinically relevant outcomes, including anhedonia and suicidality, the proposed framework delineates roles for psychiatry, nursing, and psychotherapy throughout various treatment phases. By fostering structured clinical pathways, this model aims to enhance patient safety and retention, ultimately improving the experience of those seeking help for major depressive disorder.
Abstract
Background/Objectives: Intranasal esketamine has emerged as an effective treatment for patients with treatment-resistant depression (TRD), providin...
Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine
American Journal of Therapeutics – February 20, 2026
Summary
5-MeO-DMT shows potential as a rapid treatment for depression, particularly in patients who have not responded to traditional therapies. In small-scale studies, nearly 70% of participants reported significant reductions in depressive symptoms within hours. With its ultra-short-acting nature, this psychedelic could revolutionize primary care approaches to mental health. As interest grows in psychedelics for psychiatric use, the need for larger randomized controlled trials is clear, especially given the implications for family medicine and broader health care strategies.
Abstract
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric condit...
The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review
Psychiatry Research – February 19, 2026
Summary
Ketamine and esketamine show significant promise in rapidly reducing suicidal ideation (SI) in individuals with major depressive disorder (MDD), with randomized controlled trials highlighting their short-term efficacy. Additionally, transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) also contribute to decreased depressive symptoms. However, the long-term durability of these effects remains unclear, necessitating further investigation through large-scale clinical trials. Understanding how these treatments influence overall suicidal behavior severity is crucial for advancing treatment options in psychiatry and clinical psychology.
Abstract
Ketamine, esketamine, rTMS and ECT are associated with reductions in SI in persons with MDD, with the strongest evidence from randomized controlled...
Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression
Molecular Psychiatry – February 18, 2026
Summary
Esketamine, a fast-acting antidepressant for treatment-resistant depression (TRD), shows varying effectiveness based on sex-assigned-at-birth. In a pooled analysis of five clinical trials involving 1,200 adults, females demonstrated greater overall improvement in depression severity, with higher odds of treatment response compared to males. Specifically, females exhibited significant reductions in sadness and detachment symptoms, while males had notable improvements in sadness by day 2 post-treatment. These findings highlight the necessity of considering sex-assigned-at-birth in tailoring TRD treatment approaches for better outcomes.
Abstract
Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about...
The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial
Addiction – February 16, 2026
Summary
Intravenous ketamine at a dose of 0.8 mg/kg significantly alters consciousness in individuals with alcohol use disorder. In a randomized controlled trial involving multiple infusions, participants consistently reported reduced alcohol consumption, suggesting a promising avenue for treatment. Notably, these reductions were not linked to the immediate psychoactive effects of ketamine. This highlights ketamine's potential as a novel intervention in addressing alcohol dependence and related psychiatric conditions, paving the way for innovative approaches in substance abuse treatment and outcomes.
Abstract
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects app...
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
Ketamine for depression
OpenAlex – February 10, 2026
Summary
Ketamine shows promise for individuals suffering from treatment-resistant depression, with a significant portion of patients reporting years of dissatisfaction with standard treatments. A clinical trial involving 100 participants revealed that higher, individualized doses of oral esketamine led to meaningful improvement in 40% of cases. Notably, ketamine was effective for patients with complex conditions like PTSD and those on maintenance electroconvulsive therapy. Combining ketamine with psychotherapy also demonstrated potential benefits, highlighting the need for careful monitoring and tailored approaches in psychiatric care.
Abstract
This thesis explores the use of ketamine in people with treatment-resistant depression. It starts by examining the concept of treatment-resistant d...
Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review.
Psychopharmacology – February 07, 2026
Summary
For the one-third of individuals facing treatment-resistant depression, a combined treatment approach shows promise. A review of 11 studies, selected from 768 initial results, explored Ketamine-assisted Psychotherapy (KAP). This innovative method, pairing Ketamine with Psychotherapy, was linked to reductions in depressive symptoms, with some improvements lasting up to six months. However, among the three studies with control groups, no clear difference emerged. While KAP offers potential for severe Depression, consistent evidence is still developing.
Abstract
Major Depressive Disorder (MDD) is a common and debilitating condition. Current treatments fail to provide adequate relief in roughly one-third of ...
The impact of Transcendental Meditation on psychological distress and coping in the lives of women in Uganda: A randomized controlled trial.
Health care for women international – February 05, 2026
Summary
Women living in poverty in Uganda experienced remarkable improvements in well-being after learning Transcendental Meditation. Among 199 participants, a three-month program significantly reduced perceived stress, anger, and fatigue, while boosting self-efficacy and sleep quality. An eight-month follow-up revealed enhanced physical and mental health, greater ability to handle domestic violence, and better relationships. This meditation program positively impacts psychological distress and coping, offering a valuable tool for women facing significant challenges.
Abstract
In this randomized controlled trial with women living in poverty in Uganda (n = 199) we explored the impact of Transcendental Meditation® (TM®) on ...
A Randomized Controlled Trial on the Efficacy of Ketamine vs. Electroconvulsive Therapy in Severe Depression with Suicidal Ideation.
Neuropsychobiology – February 05, 2026
Summary
Ketamine rapidly reduces suicidal thoughts, offering a promising acute intervention for severe depression. A trial of 64 patients found 31 receiving ketamine and 33 receiving electroconvulsive therapy (ECT) over two weeks. Ketamine lowered suicidal ideation scores from 12.6 to 2.0, while ECT reduced them from 12.1 to 1.2. Both treatments significantly improved depression severity, with scores dropping from around 27 to 1-2. Ketamine acted faster; ECT showed slightly greater durability. Both were effective and safe, with mild side effects.
Abstract
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressa...
Effects of mindfulness-based interventions on perceived stress among non-clinical adults: a systematic review and meta-analysis.
Npj mental health research – February 03, 2026
Summary
Mindfulness-based interventions significantly reduce perceived stress in adults. A comprehensive review of 17 randomized controlled trials, involving 1,641 participants, found that after intervention, MBI groups experienced substantially lower stress (effect size = -0.53) compared to controls. Participants engaging in mindfulness practices showed significant within-group stress reductions (effect size = 0.93), whereas control groups saw only marginal changes (effect size = 0.23). These findings confirm MBIs are effective and scalable strategies for managing stress.
Abstract
Mindfulness-based interventions (MBIs) are recognised as effective psychosocial strategies for managing stress. We conducted a systematic review an...
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review.
Clinical psychology review – February 02, 2026
Summary
Ketamine-assisted psychotherapy significantly enhances treatment engagement and symptom reduction for various psychiatric disorders, including depression and PTSD. A systematic review of 72 studies (from 64 articles) explored this promising approach. While only 11 were randomized controlled trials, and just two randomized psychotherapy within ketamine treatment, clinical effects were generally positive. However, current evidence does not definitively support added benefits from psychotherapy itself or synergy, highlighting the need for more controlled trials.
Abstract
Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining psychotherapeutic interventi...
ED95 of Ciprofol Combined with Esketamine or Sufentanil in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Dose-Finding and Randomized Controlled Trial
Drug Design Development and Therapy – February 01, 2026
Summary
Ciprofol combined with esketamine or sufentanil offers distinct sedation profiles for elderly patients undergoing endoscopic submucosal dissection (ESD). In a trial involving 112 participants, the estimated effective doses were 0.276 mg/kg for esketamine and 0.244 mg/kg for sufentanil. Notably, those receiving esketamine had shorter induction times and lower rates of hypoxia and hypotension, while experiencing longer recovery to full alertness. These findings highlight important considerations in anesthesia choices that balance efficacy and safety for older adults during surgery.
Abstract
Background: This study aimed to estimate the 95% effective dose (ED95) of ciprofol when combined with esketamine or sufentanil in elderly patients ...
Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.
European journal of anaesthesiology – January 29, 2026
Summary
Prophylactic esketamine significantly reduced postpartum depression (PPD) in new mothers undergoing elective C-sections. Among 322 primiparae, PPD incidence within three months was 11.59% with esketamine versus 20.89% without. Notably, by 7 days, only 4.89% of treated mothers developed PPD, compared to 15.19% in the control group—a 68% reduction. While preventing short-term PPD, this benefit did not extend to specific later time points. Mild side effects like dizziness (10.98%) occurred.
Abstract
Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae. This trial sought to evaluate whether prophylactic...
Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression
Journal of Ect – January 29, 2026
Summary
Combining electroconvulsive therapy (ECT) with nasal ketamine (ESK) demonstrated promising results in treating treatment-resistant depression. In a cohort of patients, this approach led to sustained symptom improvement and allowed for wider spacing between ECT sessions, potentially reducing cognitive side effects. With a focus on optimizing treatment protocols, the findings highlight the need for future randomized controlled trials to establish effective sequencing and dosing strategies. This innovative combination could reshape the treatment landscape for major depression and anxiety disorders.
Abstract
In this naturalistic series, combined ECT+ESK was feasible and associated with sustained symptom improvement, wider ECT spacing, and potentially lo...
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.
Journal of affective disorders – January 28, 2026
Summary
Patients with treatment-resistant depression were five times more likely to achieve remission with Intranasal esketamine. A systematic review and meta-analysis of nine studies synthesized real-world evidence, demonstrating substantial effectiveness (effect size of -1.98) in reducing symptoms. While 82% experienced adverse events, with dissociation in 49%, these findings highlight esketamine’s meaningful impact. This meta-analysis offers valuable insights into Intranasal esketamine's real-world effectiveness for treatment-resistant depression.
Abstract
Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generali...
Effects of low-dose esketamine on hypoxaemia during thoracoscopic non-tracheal intubation anaesthesia: protocol for a double-blind, randomised controlled trial.
BMJ open – January 27, 2026
Summary
Intraoperative Hypoxia is a significant concern during adult anaesthesia for non-intubated thoracic surgery. A new trial investigates if low-dose esketamine can reduce this risk. Patients undergoing thoracoscopic surgery will be randomly assigned 1:1 to receive either esketamine or a placebo. The primary outcome focuses on preventing hypoxaemia, defined as pulse oximetry ≤90% for at least 10 seconds. This initiative aims to enhance patient safety and recovery during these delicate procedures.
Abstract
Non-tracheal intubation anaesthesia for thoracoscopic surgery is associated with intraoperative hypoxaemia. Esketamine has both sedative and analge...
Comparing the effect of low-dose ketamine and pressure vibration mechanical device with placebo in preventing pain on propofol injection in a patient undergoing elective surgery: a double-blind, randomized control study.
Regional anesthesia and pain medicine – January 27, 2026
Summary
A simple pressure vibration device significantly reduces acute pain from propofol injections, a common issue in medical procedures. In a trial involving 275 patients, 51.1% experienced no pain with the device, compared to just 30.4% with placebo. This non-pharmacological approach also drastically cut severe pain incidence to 4.3%, down from 18.5% in the placebo group. It proved as effective for pain management as low-dose ketamine (33.0% no pain), offering a reusable solution for improving pain perception without relying on pharmacology.
Abstract
Propofol, a commonly used intravenous anesthetic induction agent, frequently produces pain on injection, with an incidence ranging from 28% to 91%....
The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence
Zenodo (CERN European Organization for Nuclear Research) – January 26, 2026
Summary
Psilocybin, a potent hallucinogen, offers rapid, sustained antidepressant effects for major depressive disorder. Clinical trials, including randomized controlled trials, show large effect sizes and higher remission rates than conventional treatments, with benefits lasting up to a year. Functional neuroimaging reveals psilocybin's impact on neuroplasticity, reducing amygdala activity and altering the default mode network. While adverse effects are mild, the integration of clinical psychology support is crucial. This neuroscience breakthrough in psychiatry medicine holds significant promise for depressive symptoms.
Abstract
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analys...
The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research – January 25, 2026
Summary
Psilocybin, a potent hallucinogen, effectively treats severe depression, offering new hope in psychiatry. A systematic review and meta-analysis of seven clinical trials, including two randomized controlled trials, found that a 25 mg psilocybin dosing regimen significantly reduced depressive severity. This therapeutic medicine's pharmacology demonstrated 25 mg as superior to 10 mg or 1 mg doses. Drawing from databases like MEDLINE for psychedelics and drug studies, this evidence suggests a promising avenue for mental health care, potentially easing the economic burden of depression.
Abstract
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not ful...
Serial ketamine infusions not effective as adjunctive care for depression
The Brown University Psychopharmacology Update – January 24, 2026
Summary
Up to eight infusions of ketamine did not outperform a psychoactive placebo in alleviating depressive symptoms among 150 inpatient participants undergoing treatment for major depression. Additionally, cognitive measures and quality of life remained unchanged compared to those receiving midazolam. These findings challenge the perceived efficacy of ketamine as an adjunctive treatment for depression, highlighting the importance of placebo effects in mental health interventions. The study underscores the necessity for continued evaluation of treatment options in addressing anxiety and depression effectively.
Abstract
Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatie...
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
Neuroscience & Biobehavioral Reviews – January 24, 2026
Summary
Psilocybin-assisted therapy offers significant antidepressant effects for major depressive disorder. A systematic review and meta-analysis of seven randomized controlled trials, involving 522 participants, revealed significant reductions in depressive symptoms. This promising intervention in clinical psychology and psychiatry observed stronger treatment effects with bodyweight-adjusted psilocybin doses and extended preparation, dosing, and integration sessions, often involving a psychotherapist. These insights from medicine and psychedelics and drug studies offer valuable guidance for standardizing future clinical trial protocols, potentially aiding those with treatment-resistant depression.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in tr...
Continuous ketamine infusion for surgical patients in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.
Critical care (London, England) – January 23, 2026
Summary
Continuous low-dose Ketamine infusion significantly reduces opioid use by 5.77 mg morphine equivalents in adult surgical ICU patients within 24 hours. A systematic review and meta-analysis of nine randomized trials involving 666 patients explored Ketamine's role in analgesia and sedation. It also lowered postoperative nausea and vomiting incidence by 41% (relative risk 0.59). While pain scores and ICU recovery outcomes like length of stay remained comparable, this comprehensive meta-analysis highlights Ketamine's benefit in opioid sparing and reducing adverse effects, offering valuable insights for critical care.
Abstract
Optimal pain and sedation management in intensive care unit (ICU) remains challenging. While opioids and benzodiazepines are widely used, their adv...
Effect of esketamine combined with ropivacaine for erector spinae plane block on postoperative analgesia of thoracoscopic surgery: a randomized clinical trial
OpenAlex – January 23, 2026
Summary
Esketamine significantly enhances pain relief following thoracoscopic surgery. In a trial involving 139 patients, those receiving an erector spinae plane block with 0.375% ropivacaine combined with 0.25 mg/kg esketamine experienced analgesia lasting 845 minutes, while those with 0.5 mg/kg esketamine enjoyed even longer relief at 895 minutes, compared to 784 minutes for the ropivacaine-only group. Patient satisfaction improved across all groups, although anxiety and depression scores remained unchanged. Notably, preoperative anxiety and smoking were linked to a need for additional pain management.
Abstract
Abstract Background There are few studies on the combination of esketamine and local anesthetic (LA) in interfascial plane block. The erector spina...
[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University – January 20, 2026
Summary
A compelling new approach to depression treatment is emerging: **psychedelic**s. **Psilocybin**, for instance, demonstrates rapid, robust, and sustained **antidepressant** effects, even for treatment-resistant cases. These compounds remarkably enhance brain **neuroplasticity**, creating a critical therapeutic "window." While precise mechanisms are still being elucidated, the **5-hydroxytryptamine receptor 2A** pathway is a central focus. This offers a unique, fast-acting intervention for a prevalent global disorder, moving beyond the limitations of current medications.
Abstract
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed ...
Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.
Addiction (Abingdon, England) – January 20, 2026
Summary
Ibogaine shows significant promise for addiction treatment, effectively reducing craving and withdrawal from opioid and cocaine dependence. However, this psychoactive compound and its metabolite, noribogaine, carry a rare but serious cardiovascular risk. It can cause QT interval prolongation and potentially fatal ventricular arrhythmias, even at therapeutic doses in healthy individuals. Variability in drug metabolism contributes to this danger. Future use demands strict medical supervision, personalized dosing, and rigorous cardiovascular monitoring, with safer ibogaine analogues showing promise.
Abstract
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive pote...
Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.
Veterinary sciences – January 19, 2026
Summary
Combining low-dose 1-cyclopropionyl lysergic acid diethylamide, a psychedelic prodrug of lysergic acid diethylamide, with ethological intervention significantly improves shelter dogs' welfare. Among 20 shelter dogs, this integrated approach consistently enhanced animal behavior, fostering greater sociability, calmness, and positive emotional reactivity. These benefits persisted for three weeks post-treatment, offering a promising new strategy rooted in ethology for improving animal welfare in stressful shelter environments.
Abstract
Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption....
Cannabis-based medicines for chronic neuropathic pain in adults.
The Cochrane database of systematic reviews – January 19, 2026
Summary
Despite popular promotion, cannabis-based medicines demonstrate no clear evidence of significantly relieving chronic neuropathic pain. A comprehensive review of 21 studies, involving 2187 participants, found that THC-dominant, balanced THC/CBD, and CBD-dominant formulations did not reliably achieve 50% pain relief compared to placebo. Balanced THC/CBD medicines showed a slight increase in patient-reported improvement (RD 0.07), but this was not clinically relevant. Furthermore, some cannabis types increased adverse events, like nervous system issues (RD 0.25 for THC-dominant).
Abstract
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neu...